Dr. Reddy's Laboratories, Incorporated

Novaliq Gmbh

Moberg Derma Ab

Engblom, Johan

Ali, Abdullah

Wahlgren, Marie

Anderson, Christopher

Johan Engblom

Frank Löscher

Ralf Grillenberger

Birgitta Svensson

Ake Lindahl

Anna Holmberg

Anette Abrahamsson

Åke Lindahl

Abdullah Ali

Marie Wahlgren

Christopher Anderson

Malin Sjöö

The present invention relates to compositions in the form of a clear solution comprising ciclosporin with low residual water content and 1-perfluorobutyl-pentane. The compositions may be used for topical administration to the eye.

Ophthalmic compositions comprising ciclosporin

The present invention relates to compositions in the form of a clear solution comprising ciclosporin with low residual water content and 1-perfluorobutylpentane. The compositions may be used for topical administration to the eye.

Single phase pharmaceutical compositions for topical application, in addition to kits and methods of use and administration are provided. The compositions comprise a biologically active agent; a delivery vehicle comprising at least a non-polymeric crystallization inhibitor and a film-former; and a volatile solvent; wherein the biologically active agent is present in the composition in a subsaturated state, the biologically active agent is present in the delivery vehicle in a supersaturated state, and the crystallization inhibitor is capable of delaying crystallization of the biologically active agent in the delivery vehicle. Biologically active agents include terbinafine and acyclovir. Treatments for onychomycosis and Varicella zoster infection, HSV-I infection or HSV-2 infection are provided.

Topical compositions

A topical composition comprising a dihydropyridine calcium antagonist, a stiffening agent and a release modifier. The stiffening agent comprises a fatty alcohol, a fatty acid sorbitane ester, or a fatty acid glycerol ester, having a hydrocarbon chain containing 12 to 22 carbon atoms and having a melting point of about 45 to 750&#xb0; C. The release modifier comprises a fatty alcohol, a fatty alcohol glycol ether, a fatty acid alkyl ester, a fatty acid glycerol ester, or a fatty acid sorbitane ester, having a hydrocarbon chain containing 12 to 18 carbon atoms and having a melting point of about &#x2212;10 to 400&#xb0; C. Use of such a composition for the treatment and/or prophylaxis of a dermal or mucosal disorder, preferably an anorectal disorder associated with high anal pressure or anal sphincter spasm.

Topical composition comprising a dihydropyridine calcium antagonist

Growing community of inventors

Lund, Sweden

Johan Engblom